Risk-reducing surgery for individuals with cancer-predisposing germline pathogenic variants and no personal cancer history: a review of current UK guidelines

[1]  C. Lázaro,et al.  ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1 , 2023, EClinicalMedicine.

[2]  J. Reis-Filho,et al.  Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations , 2023, npj Precision Oncology.

[3]  J. Ledermann,et al.  Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Schuurs-Hoeijmakers,et al.  Cancer risks by sex and variant type in PTEN Hamartoma Tumor Syndrome. , 2022, Journal of the National Cancer Institute.

[5]  C. Caldas,et al.  International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study , 2022, Gastric Cancer.

[6]  Takamichi Kuwahara,et al.  Endoscopic Management of Adenomas in the Ileal Pouch and the Rectal Remnant after Surgical Treatment in Familial Adenomatous Polyposis , 2022, Journal of clinical medicine.

[7]  S. Ellard,et al.  Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK). , 2022, Genetics in medicine : official journal of the American College of Medical Genetics.

[8]  Y. Drew,et al.  British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice. , 2021, European journal of obstetrics, gynecology, and reproductive biology.

[9]  U. Menon,et al.  Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause , 2021, BJOG : an international journal of obstetrics and gynaecology.

[10]  J. Murphy,et al.  Oncoplastic breast surgery: A guide to good practice. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  A. Howell,et al.  Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers , 2021, Journal of Medical Genetics.

[12]  A. Howell,et al.  The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer , 2021, Scientific Reports.

[13]  M. P. Douglas,et al.  Availability and funding of clinical genomic sequencing globally , 2021, BMJ Global Health.

[14]  A. Wagner,et al.  The Management of Peutz–Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline , 2021, Journal of clinical medicine.

[15]  R. Eeles,et al.  Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study , 2021, American journal of obstetrics and gynecology.

[16]  Aung Ko Win,et al.  Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report , 2020, Genetics in Medicine.

[17]  Laura H. Tang,et al.  Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. , 2020, JAMA surgery.

[18]  G. Jayson,et al.  Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England , 2020, European Journal of Human Genetics.

[19]  R. Eeles,et al.  UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants , 2020, Journal of Medical Genetics.

[20]  E. Schröck,et al.  Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome , 2020, European Journal of Human Genetics.

[21]  S. Modesitt,et al.  Optimal age for genetic cancer predisposition testing in hereditary SMARCA4 Ovarian Cancer Families: How young is too young? , 2020, Gynecologic oncology reports.

[22]  P. Møller.  The Prospective Lynch Syndrome Database reports enable evidence-based personal precision health care , 2020, Hereditary cancer in clinical practice.

[23]  J. Emery,et al.  Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study , 2020, PloS one.

[24]  G. Emons,et al.  Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review , 2020, Archives of Gynecology and Obstetrics.

[25]  Julie O. Culver,et al.  Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D , 2020, Journal of the National Cancer Institute.

[26]  C. Genestie,et al.  Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours , 2019, British Journal of Cancer.

[27]  I. Tomlinson,et al.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG) , 2019, Gut.

[28]  B. Shirts,et al.  Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers. , 2019, JAMA oncology.

[29]  J. Regimbeau,et al.  Lynch Syndrome: Current management In 2019. , 2019, Journal of visceral surgery.

[30]  B. Karlan,et al.  International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation , 2019, British Journal of Cancer.

[31]  P. Møller,et al.  The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome , 2019, Genetics in Medicine.

[32]  J. McGee,et al.  Primary Peritoneal Cancer Two Decades after a Bilateral Salpingo-Oophorectomy , 2019, Case reports in obstetrics and gynecology.

[33]  M. García-Closas,et al.  BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors , 2019, Genetics in Medicine.

[34]  S. Manley,et al.  Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.

[35]  S. Rednam,et al.  Considerations for total thyroidectomy in an adolescent with PTEN mutation , 2018, Therapeutic advances in endocrinology and metabolism.

[36]  Steven J. M. Jones,et al.  Pathogenic Germline Variants in 10,389 Adult Cancers. , 2018, Cell.

[37]  S. Ellard,et al.  p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer , 2018, The Journal of clinical endocrinology and metabolism.

[38]  R. Rouzier,et al.  Risk of Serous Endometrial Carcinoma in Women With Pathogenic BRCA1/2 Variant After Risk-Reducing Salpingo-Oophorectomy. , 2018, Journal of the National Cancer Institute.

[39]  F. van Coevorden,et al.  Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer , 2018, The British journal of surgery.

[40]  P. Fletcher,et al.  Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status , 2017, Gastrointestinal endoscopy.

[41]  Marc Tischkowitz,et al.  Clinical implications of germline mutations in breast cancer: TP53 , 2017, Breast Cancer Research and Treatment.

[42]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[43]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[44]  Shou-Bin Ning,et al.  Cancer risk in patients with Peutz–Jeghers syndrome: A retrospective cohort study of 336 cases , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[45]  D. Evans,et al.  Pathology update to the Manchester Scoring System based on testing in over 4000 families , 2017, Journal of Medical Genetics.

[46]  A. Goodman,et al.  Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act. , 2017, The oncologist.

[47]  R. Hardwick,et al.  Decision making, quality of life and prophylactic gastrectomy in carriers of pathogenic CDH1 mutations. , 2017, Translational gastroenterology and hepatology.

[48]  M. Pike,et al.  Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. , 2016, JAMA oncology.

[49]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[50]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[51]  C. Suo,et al.  PTU-145 Prophylactic total gastrectomy for hereditory gastric cancer syndrome , 2015 .

[52]  B. Fernandez,et al.  Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. , 2015, JAMA oncology.

[53]  Sarah J. Johnson,et al.  Guidelines for the management of thyroid cancer , 2014, Clinical endocrinology.

[54]  V. Brouste,et al.  High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome , 2013, Journal of Medical Genetics.

[55]  J. Sampson,et al.  Evidence for accelerated colorectal adenoma–carcinoma progression in MUTYH-associated polyposis? , 2011, Gut.

[56]  C. Caldas,et al.  Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research , 2010, Journal of Medical Genetics.

[57]  L. Boardman,et al.  Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients , 2010, Hereditary cancer in clinical practice.

[58]  C. Szczylik,et al.  Colorectal cancer in the course of familial adenomatous polyposis syndrome (“de novo” pathogenic mutation of APC gene): case report, review of the literature and genetic commentary , 2010, Archives of medical science : AMS.

[59]  C. Iacobuzio-Donahue,et al.  Risk of colorectal cancer in juvenile polyposis , 2007, Gut.

[60]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.